Clinical Trial Update: Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Telbivudine vs Tenofovir in HBeAg-negative chronic hepatitis B; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Telbivudine (telbivudine)
• Tenofovir (Tenofovir)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Hepatitis B | Phase 4 | Status: COMPLETED | Results posted: 2018-11-05